Laser Treatment for Vitiligo — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Laser treatment for vitiligo primarily refers to the 308 nanometre excimer laser (308nm XeCl excimer laser, e.g. XTRAC system), a targeted phototherapy device that delivers a high-intensity narrow-band ultraviolet B (NB-UVB) wavelength specifically to hypopigmented vitiligo patches without exposing surrounding healthy skin to ultraviolet radiation. This targeted delivery allows higher UVB doses to be used on the depigmented areas — where melanocytes are absent or non-functional — compared to full-body phototherapy, potentially achieving faster repigmentation with fewer cumulative sessions and reduced side effects to uninvolved skin. The 308nm wavelength is the therapeutic peak of the UVB spectrum for stimulating residual melanocyte stem cells in the outer root sheath of hair follicles at the lesion margin to proliferate and migrate into the depigmented epidermis, restoring pigment. The excimer laser operates in conjunction with a broad range of complementary vitiligo treatments including topical calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus cream), topical corticosteroids, systemic Janus kinase (JAK) inhibitors (ruxolitinib 1.5% cream — FDA approved for vitiligo in 2022, the first treatment specifically approved for this indication), and surgical melanocyte transplantation for stable, refractory lesions. Narrowband UVB (NB-UVB) phototherapy using a full-body phototherapy cabinet is the alternative to the targeted laser, covering larger body surface area but with lower intensity per unit area.

Laser and phototherapy treatment for vitiligo is appropriate for patients with non-segmental (generalised) vitiligo — the more common form accounting for seventy-five to eighty percent of cases — and for localised segmental vitiligo, who have active or stable disease affecting cosmetically or psychologically significant body areas. Optimal candidates for excimer laser include: patients with localised vitiligo covering less than ten to fifteen percent of body surface area, where targeted treatment is practical; those with patches in areas with good repigmentation response including the face (particularly perioral, periorbital, and cheek areas), neck, and trunk; stable vitiligo (no new lesions or lesion expansion in the past six months); and patients who have had an inadequate response from topical corticosteroids or calcineurin inhibitors alone. Full-body NB-UVB is preferred for extensive vitiligo affecting more than fifteen to twenty percent of body surface area. Patients with darker Fitzpatrick skin phototypes (IV–VI) tend to show more visible and satisfying repigmentation because the contrast between surrounding skin and the repigmenting patch is greater. Less favourable response areas include the hands, feet, and bony prominences, which have sparse hair follicle melanocyte reservoirs. Active, rapidly spreading vitiligo (Koebner phenomenon positive) is a relative contraindication to high-dose laser. Absolute contraindications include personal or family history of melanoma or xeroderma pigmentosum, photosensitising drug use, and history of radiation therapy to the treatment area.

For excimer laser treatment, the patient attends the dermatology laser clinic or phototherapy unit. Vitiligo patches are photographed for baseline documentation and Wood's lamp examination confirms lesion extent. A test dose (minimal erythema dose or MED) may be determined from a small test patch to calibrate the starting energy fluence. During treatment, the patient is seated or positioned appropriately. The excimer laser handpiece emits a circular or elliptical beam of 308nm radiation applied directly to each vitiligo patch for a defined number of pulses corresponding to a calculated energy dose in millijoules per centimetre squared. Initial doses typically begin at fifty to two hundred millijoules per centimetre squared depending on patch location and skin type, with incremental increases of ten to fifteen percent at each subsequent session as tolerance is established. Sessions last five to thirty minutes depending on the number and size of patches. The treatment protocol is two to three sessions per week; most patients receive twenty to thirty or more sessions to achieve meaningful repigmentation. Repigmentation typically begins at the lesion edge and around follicular ostia as perifollicular pigment dots, which expand and coalesce. For full-body NB-UVB, the patient stands in a phototherapy cabinet for a calibrated duration starting at the MED (determined by a test array on the inner arm) and increasing by ten percent per session. Both approaches require regular clinical review by a dermatologist to monitor response and adjust dosing.

The 308nm excimer laser achieves clinically meaningful repigmentation (defined as fifty percent or greater re-colouration of the treated lesion) in fifty to seventy-five percent of treated patches after twenty to thirty sessions in published series. Facial lesions — particularly periorbital and perioral patches — respond most favourably, with greater than seventy-five percent repigmentation in sixty to seventy percent of cases. A systematic review (Bae et al., Journal of Dermatological Treatment, 2018) found the excimer laser produced superior facial repigmentation rates compared to full-body NB-UVB phototherapy, attributed to higher targeted doses achievable without whole-body UV exposure. The landmark randomised trial of ruxolitinib 1.5% cream (JAK inhibitor) plus NB-UVB versus either treatment alone (TRuE-V study, NEJM 2022) demonstrated substantially superior facial repigmentation with the combination — seventy-five percent achieved at least twenty-five percent improvement on the F-VASI score at twenty-four weeks — highlighting the benefit of combining JAK inhibitor cream with phototherapy. Excimer laser produces cosmetically meaningful colour match to surrounding skin, improving psychological well-being and health-related quality of life scores (DLQI) significantly in responders. Vitiligo, particularly of the face and hands, carries substantial psychosocial burden, and successful repigmentation correlates with meaningful improvements in self-esteem, social functioning, and depression and anxiety scores in multiple validated studies.

Excimer laser treatment is a well-tolerated outpatient procedure. The principal side effect is phototoxic erythema (redness, sunburn-like reaction) in the treated area at twenty-four to forty-eight hours post-session, caused by excessive UV dose relative to the skin's tolerance. Mild erythema is desirable and indicates a therapeutic dose; painful or blistering erythema indicates the dose should be reduced at the next session. Hyperpigmentation (darkening) of the skin at the border of the treated area — where some normal melanocytes receive additional UV stimulation — can create a colour mismatch and is a common cosmetic concern that is usually temporary and resolves within weeks to months after treatment completion. With the targeted excimer laser approach — unlike full-body NB-UVB — cumulative total body UV dose is lower, reducing theoretical long-term risks of photoageing and skin cancer. However, treatment of the same area over many sessions carries a cumulative UV dose warranting careful dose tracking by the treating dermatologist. Patients should use broad-spectrum sunscreen SPF 30 or higher on treated areas between sessions to protect fragile repigmenting skin. Patients with a history of HSV (herpes simplex) in or near the treatment area may experience reactivation from UV exposure; prophylactic antiviral medication (aciclovir 400 mg twice daily) is appropriate. Response is incomplete in a significant minority — approximately thirty percent of patients achieve less than twenty-five percent repigmentation — and maintenance sessions may be required.

No downtime or recovery is required after excimer laser sessions. Mild skin redness and warmth in treated patches is expected for twenty-four to seventy-two hours after each session and can be soothed with cool water application or an over-the-counter ceramide moisturiser. Prescribed topical treatments — ruxolitinib cream, tacrolimus, or topical corticosteroids — should be applied to treated patches on non-laser days or as directed by the dermatologist to enhance the synergistic effect. A broad-spectrum sunscreen SPF 30 or above must be applied to all exposed vitiligo patches daily, as depigmented skin contains no melanin and has no natural UV protection — prolonged sun exposure causes painful sunburn in vitiligo lesions. Patients should avoid sunbathing and use protective clothing on sunny days. Response assessment is typically performed at session twenty to thirty by photography and clinical assessment. Patients who achieve satisfactory repigmentation may enter a maintenance protocol of monthly sessions to sustain colour, as repigmented areas can lose pigment if UV stimulus is withdrawn abruptly. Long-term management of vitiligo requires ongoing dermatological follow-up, as the condition has an unpredictable natural history with potential reactivation of depigmentation even in successfully treated areas.